</Agent System Instructions>
<Blinded Review: TIME_ANON_0074>
**Composite Score:** 9.2 / 10.0 (Rigor: 3.2/3.5 | Claims: 2.3/2.5 | Biology: 1.9/2.0 | Reproducibility: 1.8/2.0)
**Bias Category:** None (Methodologically Sound)
**Verdict:** Minor Revision
**Study Modality:** Wet-Lab Primary Experimental
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Basic/Mechanistic Discovery

---

### 1. Executive Summary
This study isolates and characterizes `slt2-1`, a temperature-sensitive allele of the *Saccharomyces cerevisiae* MAP kinase gene `SLT2` (`MPK1`), identified through a synthetic-lethal (colethal) screen with the Start-defective `cdc28-109` allele. Through classic yeast genetics, quantitative morphometry, time-lapse differential interference contrast (DIC) microscopy, fluorescence staining of chitin and cortical actin, and transmission electron microscopy (TEM), the authors demonstrate that `slt2` mutants display hallmark defects of polarized cell growth and the actin cytoskeleton: cell-size heterogeneity (stillborn small pear-shaped buds alongside enlarged spherical mother cells), delocalized chitin deposition and cortical actin patches, and cytoplasmic accumulation of secretory vesicles and cisternal membranes closely phenocopying `act1-1` and `myo2-66`. Tetrad dissection coupled with `URA3` plasmid counterselection on 5-FOA conclusively proves that `slt2::HIS3` is synthetically lethal with both `act1-1` and `myo2-66`.

### 2. Methodological & Statistical Audit
- **Genetic Screen & Allele Specificity:** The synthetic lethality screen using `YEp24-CDC28` (`URA3`) and 5-FOA counterselection at the semi-permissive temperature ($28^\circ\text{C}$) was rigorously validated by backcrossing (`slt2-1` colethality with `cdc28-109` and $37^\circ\text{C}$ ts growth co-segregated in 12/12 tetrads) and targeted chromosomal integration of `YIp-URA3-SLT2` (0 recombinants in 10 complete tetrads). Crossing `slt2-1` to phase-specific `cdc28` alleles cleanly separated G1 from G2 functions: `slt2-1 cdc28-4` (G1-defective) showed synthetic slow growth at $24^\circ\text{C}$ and lethality at $30^\circ\text{C}$, whereas `slt2-1 cdc28-1N` (G2/M-defective) showed no synthetic defect.
- **Control of Strain Background Modifiers:** When initial crosses of `slt2-1` with non-isogenic `act1-1` and `myo2-66` strains yielded ~10% viable double-mutant spores across $\ge 20$ tetrads, the authors astutely identified background polymorphism (`SSD1-v` vs. `ssd1-d`) as a modifier and redesigned the experiment using the null disruption `slt2::HIS3` covered by `pFL44-SLT2` (`URA3`). Replica-plating complete tetrads onto 5-FOA at $24^\circ\text{C}$ proved 100% synthetic lethality of `slt2::HIS3 act1-1` and `slt2::HIS3 myo2-66` (10/10 tetrads, Fig. 8).
- **Quantitative Cell Morphometry & Viability:** Cell volumes were quantified using prolate ellipsoid geometry ($V = \frac{4}{3}\pi ab^2$) on $n \ge 250$ cells per condition across $24^\circ\text{C}$, $30^\circ\text{C}$, and $37^\circ\text{C}$ comparing `CMY678` (`slt2-1`) against its isogenic `SLT2+` integrant `CML6` (Fig. 2). Time-lapse microscopy over 24 h directly tracked individual pear-shaped daughter cells to prove they are stillborn (Fig. 3).
- **Minor Quantitative Omission:** While the EM images (Fig. 7) and fluorescence micrographs (Figs. 5–6) are visually compelling and compared directly alongside `act1-1`, `myo2-66`, and isogenic wild-type controls (with 0.8 M sorbitol osmotic stabilization controlled on both WT and mutant), the manuscript does not tabulate the exact percentage of cells exhibiting delocalized actin patches or vesicle accumulation across a counted sample of cells.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** *"slt2 mutants exhibit phenotypes similar to those shown by mutants of the yeast actin cytoskeleton, including delocalization of chitin deposition and of actin cortical spots and the accumulation of secretory pathway membranes and vesicles."* — `[Well Supported]`
  - Directly demonstrated by volume histograms (Fig. 2), Calcofluor staining (Fig. 5), rhodamine-phalloidin staining in 0.8 M sorbitol (Fig. 6), and side-by-side reduced-osmium TEM sections of `slt2::HIS3`, `myo2-66`, and `act1-1` (Fig. 7).
- **Claim 2:** *"slt2::HIS3 act1-1 and slt2::HIS3 myo2-66 double mutants are inviable."* — `[Well Supported]`
  - Conclusively proven by tetrad dissection and 5-FOA plasmid loss assays (Fig. 8).
- **Claim 3:** *"We suggest that Slt2p functions downstream or in parallel with Cdc28p in promoting bud formation and apical growth."* — `[Well Supported]`
  - The authors appropriately frame this as a genetic model ("downstream or in parallel") and explicitly note in the Discussion that direct biochemical kinase assays will be required to test whether Slt2p activation depends on Cdc28p or Pkc1p across the cell cycle.

### 4. Reproducibility & Data Completeness
- **Strain & Plasmid Documentation:** Table I provides complete genotypes and sources for all 16 yeast strains (`CMY678` through `CMY715`), including the exact construction of isogenic `SLT2+` controls (`CML6`, `CML13`) and the `slt2::HIS3` disruption allele (replacing a 1.3-kb *Hind*III internal fragment with a 1.7-kb *HIS3* cassette).
- **Sequence & Methodological Precision:** Nucleotide and amino acid differences between the cloned `SLT2` locus and the published sequence (C at nt 1035 giving Val126Leu; CG at nt 2270–2271 giving Thr467Ser) are documented in detail, and all microscopy fixation and staining protocols are fully reproducible.
</Blinded Review: TIME_ANON_0074>
